Off-Label Worries Could Be Solved By Studies, Not Speech Reg Overhaul, FDA Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Par’s suit challenging its off-label promotion regulations is unfounded since the agency would not take action against speech to doctors who prescribe Megace ES for both approved and unapproved uses. FDA also lays out the rationale for its off-label promotion rules from DESI to Prempro.
You may also be interested in...
Par Pursuing Settlement Of FDA Suit And DoJ Off-Label Investigation
Parties have stayed their litigation as they continue to hammer out a potential global resolution that would also settle DoJ’s investigation of Megace sales and marketing practices.
When Is On-Label Speech Off-Label Promotion? Par Links The Two In Suit Against FDA
Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.
FDA Off-Label Regs Face Cave-In Risk After Supreme Court Data-Mining Ruling
Lawyers have pored over the Supreme Court's decision overturning Vermont's prescriber data mining law to see how it may be applied to other forms of pharmaceutical marketing.